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Ethnobotanical relevance: Due to the global rise in the use of traditional Chinese medicine (TCM), Chinese
materia medica (medicinal materials, or CMM) are giving cause for concern over their evidence base,
safety/possible toxicity, questionable quality and use of endangered species of both animals and plants.
However, little if anything is actually known about the range of species used to produce CMM used in
Europe and even in China. This study represents the ﬁrst attempt to identify and compare the most
important CMM used in both regions, to begin the process of assessing the risks to public health and
possible future beneﬁts.
Materials and methods: Data were collected from a convenience sample of TCM practitioners in the EU
and mainland China, using a paper/online survey. Among other questions, respondents were asked (1)
which conditions they most commonly treated using CMM and the likelihood of them using herbal
manufactured products and decoctions in addition to raw herbs; (2) the perceived frequency with which
they observed adverse events to CMM; (3) the frequency and reasons for use of 1 herbal formula and
6 speciﬁc individual herbs; (4) an open question about other CMM they used, including materials of non-
plant origin. Data were entered into PASW statistics package and analysed using frequency tables, cross-
tabulations and chi-squared tests to compare EU and Chinese results.
Results: From a total of 747 useable questionnaires (420 from China, 327 from the EU) of those
responding from the EU, TCM was generally more commonly used for obstetric/gynaecological and
dermatological conditions, compared to neurological and gastrointestinal diseases in China. Disorders
treated by Chinese practitioners were more varied, and often more serious, than those treated by their
European counterparts, and the range of materials used in China was wider. The potential for toxicity was
not high in either region, but although greater in China due to the use of more potent CMM, the
incidence of side effects was perceived to be higher by EU practitioners.
Conclusions: Very few of the species used to prepare CMM in the EU in this study give rise to safety
concerns fromwhat is known from the scientiﬁc and other literature, and in China only a few toxic CMM
appear to be commonly used, some of them only after processing and mainly for serious disorders. The
main cause for concern is likely to be interaction with prescribed medication, especially in central
nervous system and cardiovascular conditions where drug interactions have previously been reported
most frequently and which would currently be more applicable in China than Europe.
& 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Traditional Chinese medicine (TCM) plays an important role
in healthcare in South-East Asia, and increasingly so in the West.d Ltd. All rights reserved.
: +44 118 378 6562.
E.M. Williamson),The US spent US$7.6 billion in 2010 on TCM products from China
(Cheung, 2011), and in Europe, exports of TCM products amounted
to US$2 billion (Liu et al., 2009). As of May 2011, China had signed
91 TCM partnership agreements with over 70 countries, and
investment in TCM research by the Chinese government reached
US$770.5 million in 2010 (Cheung, 2011).
One of the mainstays of TCM is the use of herbal, animal and
mineral-derived medicines, Chinese materia medica (or medicinal
materials; CMM), and some of these are now giving cause for
E.M Williamson et al. / Journal of Ethnopharmacology 149 (2013) 453–462454concern over their appropriate use, evidence base, possible toxi-
city, potential for interaction with prescription and other drugs,
questionable quality and use of endangered species of both
animals and plants. The MHRA (UK Medicines and Healthcare
Regulatory Agency) has identiﬁed 16 areas of risk for such
medicines (MHRA, 2006) but surprisingly, very little, if anything
is actually known about the range of CMM used in Europe and
even in China. This study represents the ﬁrst modern attempt to
identify the most important materia medica used on both con-
tinents, to begin the process of assessing their risks to public
health and possible future beneﬁts.
CMM are of mainly herbal origin but also include animal parts,
giving rise to other concerns such as pathogen contamination and
the use of endangered species. There are no data available on the
proportions of CMM from animal sources, although animal med-
icines are thought likely to be less popular in Europe than in China,
for cultural and legal reasons. In China, injectable products derived
from herbal materials are widely used, but in the EU, parenteral
preparations can only be supplied on the prescription of a medical
practitioner qualiﬁed in the EU (Council Directive 2001/83/EC),
and normally these would be licensed products. For these reasons,
and to focus on the use of particular species, injectable products
were not included in the survey, nor were decoction granules or
patent formulae, with the exception of liuweidihuang (LW) which
as a popular formula in both China and Europe, was surveyed
speciﬁcally.
As TCM becomes ever more widely used within the European
Union (EU), many high streets in the UK and elsewhere now have
outlets which sell Chinese medicines, either on request or after
consultation with a member of staff who may or may not have any
appropriate biomedical or medical qualiﬁcations. The number of TCM
practitioners in the EU, and their qualiﬁcations and range of expertise,
is also unknown since TCM is currently unregulated, although plans
were announced in February 2011 by the UK Department of Health to
regulate all herbal practitioners (MHRA, 2011). Individual practitioners
also practise very differently, depending on their training and educa-
tion, with many using a variety of approaches in addition to CMM
within their treatments (Robinson et al., 2012).
As a result of these concerns, the EU recently supported
a programme of EU-China collaborative research, the Good Practice
in traditional Chinese medicine (GP-TCM) programme, under the
European Commission's Framework 7 (FP7) programme to investigate
the practice of TCM in Europe and to provide recommendations for
future research initiatives including the more pressing safety questions
(Uzuner et al., 2012). This study is part of that networking platform
and attempts to map the use of speciﬁc CMM in Europe and China by
surveying practitioners in both regions. The intention is that the data
will ultimately contribute to the development of clinical guidelines for
TCM usage and international regulation, as well as signal areas which
would be fruitful for further research.2. Methods
Data were collected using methods described previously, as
part of a larger survey also exploring the practice of acupuncture
in both regions (Robinson et al., 2012). Brieﬂy, a convenience
sample of TCM practitioners in the EU (contacted via email by
their professional organisations) and in mainland China (from
geographically dispersed hospitals) was invited to participate in
a survey conducted during 2010/2011. Practitioners' demographic
details, education and training were recorded, and respondents
were asked questions which included (1) which conditions they
most commonly treated using CMM and the likelihood of them
using herbal manufactured products and decoctions in addition to
raw herbs; (2) the perceived frequency with which they observedadverse events to CMM; (3) the frequency of use of 1 herbal
formula and 6 speciﬁc individual herbs (4) an open question about
other CMM they used, to include materials of non-plant origin.
The formula liuweidihuang (‘Six Ingredient Rehmannia') was
surveyed speciﬁcally. LW is a traditional Chinese medicine con-
taining six herbs: Rehmannia glutinosa (Gaertn.) DC. root; Cornus
ofﬁcinalis Siebold & Zucc. fruit; Dioscorea opposita Thunb. tuber;
Wolﬁporia extensa (Peck) Ginns (better known by its synonym,
Poria cocos F.A. Wolf) fungus; Alisma plantago-aquatica subsp.
orientale (Sam.) Sam. rhizome, and Paeonia suffruticosa bark Andr.
(Huang et al., 2012). It is traditionally used to improve age-related
diseases, such as impaired mobility, vision, hearing, cognition and
memory, and female conditions.
The six individual herbs speciﬁed in the questionnaire
were: Ganoderma lucidum (Curtis) P. Karst and other species
(lingzhi); Angelica pubescens Maxim. (duhuo); Astragalus membra-
naceus Bge (huangqi); Atractylodes macrocephala Koidz (baizhu);
Scutellaria baicalensis Georgi (Huang Qin); and Tripterygium wil-
fordii Hook f (leigongten).
Since no survey has yet been carried out on the use of CMM on
both continents, these CMM were chosen as a starting point based on
sales and popularity, using a consensus method from lists from
companies trading species used in TCM in mainland China, Hong
Kong and Europe, as well as lists from practitioner colleagues in China
and Hong Kong and colleagues involved in the GP-TCM consortium.
Tripterygium wilfordii was included because, although not one of the
most important CMM, it has well-documented toxicity and one of the
main aims of this study was to explore the use of toxic CMM in Europe
compared to China. The formula liuweidihuang was included because
it is widely used and available in both China and the EU. This paper
reports only data from respondents using CMM in their practice. Data
were coded and entered onto PASW statistics v18 to generate
frequency data. Cross tabulations were generated and chi- squared
tests were used to compare EU and Chinese results.
In open questions, CMM were cited by respondents under various
names which were not necessarily accepted names or complete
enough to identify the method of processing. Some respondents used
abbreviations, including for botanical names, and some used Chinese
characters only. Pinyin names were often written with a space to
indicate to the non-Chinese speaker that there are 2 or more
characters or words and rarely, English common names were given.
To interpret these, the Chinese Pharmacopoeia 2010 English edition
(Chinese Pharmacopoeia Commission, 2010) was consulted for species
used and accepted pinyin names, and plant species names were
authenticated using the Royal Botanical Gardens Kew data base,
‘The Plant List’ as is recommended good practice (Chan et al., 2012).
A TCM practitioner (one of the authors, A Booker) was consulted
regarding any ambiguous Chinese terms (e.g. ‘shu di’ for ‘shudihuang’)
to ensure as much conﬁdence as possible in the accuracy of the CMM
cited. In this study, we have used the Chinese convention of citing the
pinyin name as a single word but entries are classiﬁed in the tables
under accepted species scientiﬁc name, as this is the most accurate
way of identifying the origin of the material (Chan et al., 2012; Shaw
et al., 2012) and in some instances the part of the plant was omitted,
so the pharmaceutical drug name could not always be used. Unin-
telligible entries were rare: 3 from the EU, which were omitted from
the analysis, and none from China.3. Results
3.1. Responses and demographics of practitioners
A total of 1112 responses were received from TCM practitioners
(including acupuncturists), with 747 useable questionnaires (relat-
ing to herbal practice) received (420 from China, 327 from the EU).
Fig. 1. Conditions commonly treated by practitioners in China and the EU.
E.M Williamson et al. / Journal of Ethnopharmacology 149 (2013) 453–462 455The response rate for EU practitioners could not be calculated as it
was a convenience sample; however for the Chinese sample,
which was purposive, there was a 98% completion rate. A total
of 365 questionnaires were excluded as they were from countries
not in the EU or China, incomplete, or only practised acupuncture
and did not practice herbal medicine. This gave a total of 747
useable questionnaires for analysis, 420 from China, 327 from the
EU (from 12 different countries: UK, Spain, Italy, Switzerland,
Germany, Netherlands, Belgium, Slovenia, Portugal, Ireland, Sweden,
Czech Republic). The results represent a convenience sample con-
trolled by the logistics of the consortium and their links with
practitioners, and we received no responses from Austria for exam-
ple, or some other countries with a well-developed tradition of TCM.
This study is intended to provide a preliminary evidence to use as a
foundation for further research and cannot be considered to be
representative for all of Europe Table 1.
Key points to note are that the Chinese practitioners were
younger, therefore had practised for less time, and were more
likely to have received biomedical training.
3.2. Comparison of commonly treated conditions by practitioners in
China and the EU
Practitioners were asked their views on the conditions they
normally treat using CMM. A different range of conditions were
treated in China compared to the EU, as shown in Fig. 1. The most
common indications for which CMM were used in the EU were, in
order of prevalence, obstetric/gynaecological, dermatological, gas-
trointestinal, psychiatric, stress-related and allergic disorders,
whereas in China they were neurological, gastrointestinal, respira-
tory, pain, obstetric/gynaecological and cardiovascular conditions.
In China, the conditions treated appear to be often more
serious, and also generally less likely to be of psychiatric or
stress-related origin than in Europe. In the survey of acupuncture
use (Robinson et al., 2012), blood disorders were differentiated
from cardiovascular disorders, however as can be seen here, no
practitioners gave a response for ‘blood disorders’.
3.3. The use of herbal manufactured products and decoctions
EU practitioners were much less likely to use herbal decoc-
tions: 49.8% did not, compared to 11.9% of Chinese (po0.001),
especially those who had trained at least partly outside China, but
practitioners in both regions were equally likely to use herbalTable 1
Demographics of practitioner samples in China and the EU.
Demographics EU
N (% of sample)
China
N (% of sample)
Gender
Female 130 (40%) 224 (53%)
Male 113 (35%) 182 (43%)
Missing 84 14
Age
18 to 29 7 154 (37%)
30 to 39 50 (15%) 169 (40%)
40 to 49 100 (31%) 68 (16%)
50 to 59 73 (22%) 12
Over 60 14 1
Missing 83 16
Biomedical trainingn
Western doctor 108 (33%) 266 (63%)
Western nurse 20 (6%) 0
Physiotherapist 17 57 (14%)
Dietician 14 20 (5%)
n The remainder were TCM-trained but did not have any western conventional
medical training.manufactured products rather than raw herbs (84% of both EU and
Chinese); po0.001 with the exception of injectable products,
which were not used by EU practitioners for legal reasons. Extract
granules for reconstitution are becoming increasingly important
products in both China and the EU (see e.g. Luo et al., 2012), but
respondents did not necessarily indication the formulation used so
this data could not be collated independently.
3.4. Comparison of adverse events reported in China and the EU
Practitioners were asked about their perceptions, based on
their own experience, of the incidence of adverse events to CMMs
in general. Speciﬁc reactions to particular CMMs were not sought;
the question was designed to ﬁnd the overall impression of the
safety of the materials used by practitioners.
It is noteworthy that Chinese herbalists were less likely to
report seeing adverse events to CMM in practice (po0.001) and
more likely to consider their incidence to be ‘rare’ or ‘very rare’.
Surprisingly however, EU respondents were more likely to say they
‘never’ experienced adverse events Fig. 2.
3.5. Comparison of the use of speciﬁc CMM in China and the EU
3.5.1. The formula liuweidihuang
This formula is used for a wide variety of conditions which are
considered in TCM theory to be due to ‘kidney yin deﬁciency’.
These include many degenerative disorders and those of ageing, as
well as menopausal symptoms and to a lesser extent, menstrual
problems and infertility. Other indications were low back pain,
tinnitus, arthritis, fatigue, diabetes, dry mouth, and dry skin.
Fig. 3 shows that the herbal formula liuweidihuang was more
commonly used in China, with 80.3% of practitioners using it
commonly or very commonly compared to 64.2% for EU practi-
tioners (po0.001). These results conﬁrm the popularity of the
formula, justifying its inclusion in the survey.
3.5.2. The speciﬁc herbs
Five of the six named herbs (Ganoderma lucidum/Gleditsia
sinensis, Angelica pubescens, Astragalus membranaceus, Atractylodes
macrocephala, Scutellaria baicalensis) were used widely in both
continents, conﬁrming the validity of the consensus method by
which they were selected for investigation. Tripterygium wilfordii
was more rarely used in the EU (5%, compared to 17% in China),
Fig. 2. Practitioners' perceptions of adverse events due to CMM.
Fig. 3. Use of Liu Wei Di Huang in China and the EU.
E.M Williamson et al. / Journal of Ethnopharmacology 149 (2013) 453–462456but even this European usage was considered very high, and since
response numbers were quite low, it may not be representative of
the actual use. With the exception of Ganoderma (50% of EU
compared to 35% in China), the use of these herbs was also
mentioned more frequently in China than the EU. Results are
shown in Table 2, with full botanical names, synonyms, pinyin and
common names and parts of plants used.
Most respondents gave Chinese diagnoses for the use of the
speciﬁc herbs, and many said they used them for a range of
symptoms/conditions. For those that could be classiﬁed: Angelica
pubescens was generally used for pain and rheumatism/arthritis in
both areas, whereas Astragalus membranaceus was used for improv-
ing immune function in the EU (18.5% of all conditions) but for
gastrointestinal problems in China (26.1% of conditions). Atractylodes
macrocephala was commonly used for gastrointestinal disorders
(45.2% in the EU and 24.0% in China) and Scutellaria baicalensis for
dermatological and respiratory indications. Lingzhi (Ganoderma) wasmost commonly used for low energy, general wellbeing and improv-
ing immunity, and for chronic conditions including cancer support,
allergies, respiratory, obstetric and gynecological disorders, and
insomnia. Leigongteng (Tripterygium), a toxic herb, is used for the
treatment of rheumatoid arthritis and has some anti-cancer proper-
ties. These ﬁndings are therefore consistent with the cited ‘conditions
most commonly treated’ in each region, as shown in Fig. 1.
Those respondents who did not use the speciﬁed herbs cited
‘I only use patent herbs’ or ‘I only use them in formulas’ as their
main reasons, which is entirely compatible with TCM theory
where more than one herb is normally used for a particular
condition. However, these herbs are likely to be constituents of
such formulae, in which case their usage would not have been
recorded in this survey.
3.5.3. Other herbs
The frequency of use of other herbs (in response to open
questions) is also shown in Table 2. The most commonly used
were: Angelica sinensis (Oliv.) Diels, Paeonia lactiﬂora Pall., Rehmannia
glutinosa (Gaertn.) DC, Glycyrrhiza glabra L./Glycyrrhiza uralensis
Fisch/Glycyrrhiza inﬂata Bat, Ligusticum striatum W.T. Aiton, Panax
ginseng CA Meyer (and other spp. of Panax), and Wolﬁporia extensa
(syn Poria cocos). A wide range of herbs was used at low frequencies,
but surprisingly, several important TCM drugs which were thought
to be commonly used in Europe did not show up in this list, for
example Lilium brownii (baihe) and Corydalis yanhusuo (yanhusuo).
The reasons for this are not known, but should be investigated in
future to identify any misinterpretations and unexpected limitations
involved in this type of study.
3.5.4. Non-plant CMM
The use of non-plant species used to prepare CMM is given in
Table 3; all were more commonly used in China. The most widely
used CMM of animal origin were oyster shell, earthworm, cen-
tipede, and silkworm. Exotic and illegal materials such as rhino
horn and tiger bones were not mentioned by any of the respon-
dents either in China or the EU.4. Discussion
To our knowledge, this is the ﬁrst study to survey the range of
species and materials used in TCM and compare them between
China and the EU, and to assess them from a safety point of view.
We have found signiﬁcant differences in the conditions treated
using CMM, which were in fact very similar to those found in
the acupuncture survey (Robinson et al., 2012), reﬂecting the
frequency of conditions treated in both continents, the materials
used and their recorded safety. Disorders treated by Chinese
practitioners were more varied, and often more serious, than
those treated by their European counterparts, and the range of
materials used in China was wider. The potential for toxicity was
not high in either region, but although greater in China due to the
use of more potent CMM, the incidence of side effects was
perceived to be higher by EU practitioners. We propose further
explanations for these differences: availability of speciﬁc Chinese
materia medica, cost, regulation, and patient characteristics and/or
treatment-seeking behaviour. The education of practitioners will
obviously inﬂuence prescribing habits, but there is no information
available about this to compare.
4.1. Availability and cost
Although no ﬁgures are available, it seems reasonable to infer
that Chinese people are likely to choose a favoured over-the-
counter remedy to treat minor disorders, whereas Europeans are
Table 2
Comparison of individual herb species usage by TCM practitioners in China and the EU.
Botanical species source;
toxicity notes (where known, on shaded entries)
Herb: pinyin, common name(s) and plant part EU herbalists
citing herb
(n¼327)
Chinese
herbalists citing
herb (n¼348)
N Approx %
responders
N Approx %
responders
Astragalus membranaceus Bgen Huangqi; Membranous milk-vetch root 210 64 335 96
Atractylodes macrocephala Koidzn Baizhu; Bighead or white actractylodes rhizome 204 62 329 95
Scutellaria baicalensis Georgin Huangqin; Baical skullcap root 190 58 300 86
Angelica pubescens Maxim.n Duhuo; Pubescent angelica root 170 52 231 66
Ganoderma lucidum (Curtis) P. Karst and other spp.n Lingzhi; Glossy ganoderma; Divine mushroom 163 50 122 35
Angelica sinensis (Oliv.) Diels Danggui; Chinese angelica root 51 15 56 16
Paeonia lactiﬂora Pall. Baishao/Chishao; White/red peony root 47 14 35 10
Rehmannia glutinosa (Gaertn.) DC. (prepared/raw or not stated) Shengdihuang (raw); Shudihuang (prep). Chinese
foxglove root
37 11 30 9
Glycyrrhiza glabra L., G. uralensis Fisch. Gancao; Liquorice root 34 10 27 8
Ligusticum striatum DC (L. wallichii Franch). Chuanxiong; Chinese/Szechuan lovage root 32 8 32 9
Panax ginseng CA Meyer and other spp. of Panax Renshen; Ginseng root 31 9 10 3
Lycium chinensis Mill.; L. barbarum L. (berries/root bark). Gouqizi (berry; L. barbarum only); Dìgupí (root bark).
Wolfberry; goji berry
30
2
9 0 1 0 o1
Codonopsis pilosula (Franch.) Nannf./C. tangshen Oliv. Dangshen; Bonnet bellﬂower; False or Poor man's
ginseng root
25 8 54 15
Wolﬁporia extensa (Peck) Ginns (syn Poria cocos F.A. Wolf). Fuling; Hoelen, Poria, Tuckahoe sclerotium/fungus 23 7 60 17
Bupleurum chinense DC., B. scorzonerifolium Willd., B. falcatum L. Chaihu; Chinese thorowax/Hare's ear root 21 6 44 37
Salvia miltiorhiza Bunge Danshen; Chinese/Red sage root 20 6 16 5
Tripterygium wilfordii Hook.fn Triptolide is toxic and
immunosuppressant
Leigongteng; Thunder-god vine root 17 5 58 17
Phellodendron amurense Rupr.; P. chinense C.K. Schneid. Huangbo/Huangbai; Amur/Chinese cork tree bark 15 5 1 o1
Zingiber ofﬁcinale Roscoe (dried; fresh; unspeciﬁed) Ganjiang (dried); Shengjiang (fresh); Ginger rhizome 15 5 3 o1
Ziziphus jujube Mill. var. spinosa (Bunge) Hu ex H.F. Chou Suanzaoren; Sour/spiny date seed 14 4 2 o1
Coptis chinensis Franch Huanglian;Chinese goldthread rhizome 14 4 3 o1
Anemarrhena asphodeloides Bge. Zhimu; Anemarrhena rhizome 12 o4 1 o1
Lonicera japonica Thunb. Jinyinhua; Japanese honeysuckle ﬂower 12 o4 6 o2
Chrysanthemum morifolium Ramat Juhua; Florist's chrysanthemum 12 o4 7 2
Pinellia ternata (Thunb.) Makino Toxic unless processed (contains
calcium oxalate needle crystals and lectins)
Banxia; Crow-dipper rhizome 11 3 27 8
Forsythia suspensa (Thunb.) Vahl. Lianqiao; Forsythia fruit 11 3 5 o2
Citrus reticulata Blanco, C. aurantium L. Potential toxicity in excessive
amounts (synephrine content)
Chenpi; Tangerine/orange ripe fruit peel. Zhiqiao; the
whole sliced fruits
11 3 27 8
Paeonia suffruticosa Andr. Mudanpi; Tree peony root 11 3 6 o2
Curcuma longa L. and related spp Jianghuang, Yujin; Turmeric rhizome 11 3 2 o1
Cyperus rotundus L. Xiangfu; Nut sedge tuber 11 3 1 o1
Prunus persica L. Stokes Potential toxicity (cyanide release from
amygdalin)
Taoren; Peach seed kernel 10 3 19 6
Carthamus tinctorius L. Honghua; Safﬂower 9 o3 29 8
Cinnamomum cassia (Nees & T. Nees) bark/twig Rougui; guizhi; Cassia/Chinese or false cinnamon/bark
or twig
9 o3 31 9
Saposhnikovia divaricata (Turcz.) Schischk (¼Ledebouriella divaricata
(Turcz.) Hiroë)
Fangfeng; Ledebouriella root 9 o3 8 2
Gardenia jasminoides Ellis Zhizi; Cape jessamine fruit 9 o3 1 o1
Mentha canadensis L. (¼M. haplocalyx Briq. Field) and other spp e.g.
Mentha aquatica L.)
Bohe; Corn mint (water mint etc) herb 9 o3 1 o1
Eucommia ulmoides Oliv. Duzhong; Chinese/hardy rubber tree bark 8 2 11 3
Fallopia multiﬂora (Thunb.) Haraldson (Polygonum multiﬂorum
Thunb.)
Heshouwu/Shouwuteng/Foti; Fleece ﬂower root/stem/
herb
8 2 3 o1
Rheum palmatum L. and others Dahuang; Chinese rhubarb root/rhizome 8 2 10 3
Dioscorea opposita Thunb. Shanyao; Chinese yam tuber 7 2 15 4
Angelica dahurica (Hoffm.) Benth. & Hook.f. ex Franch. & Sav. Baizhi; Wild/fragrant angelica root 7 2 4 1
Scrophularia ningpoensis Hemsl. Xuanshen;Ningpo ﬁgwort root 7 2 2 o1
Citrus aurantium L., or Citrus sinensis (L.) Osbeck Potential toxicity
(due to presence of synephrine)
Qingpi; Orange (immature fruit) peel 7 2 7 2
Albizia julibrissin Durazz. Hehuanpi; Mimosa/Silk tree; Tree of Happiness bark 7 2 0 0
Ziziphus jujuba Mill Dazao; Jujube fruit 7 2 2 o1
Ophiopogon japonicus (Thunb.) Ker-Gawl. Maimendong; Mondo grass root 6 o2 11 3
Gastrodia elata Blume. †Endangered species Tianma; Japanese orchid tuber 6 o2 13 4
Pueraria montana var. lobata (Willd.) Sanjappa & Pradeep Gegen; Kudzu vine root 6 o2 10 3
Cuscuta chinensis Lam. Tusizi; Chinese dodder seed 6 o2 7 2
Polygala tenuifolia Willd. Yuanzhi; Chinese senega root 6 1 2 o1
Schisandra chinensis (Turcz) Baill. Wuweizi; Magnoliavine fruit 5 o2 8 2
Uncaria rhynchophylla (Miq.) Miq. ex Havil.; U. sinensis (Oliv.)
Havil.; U. macrophylla Wall.
Gouteng; Gambir stems and thorns 5 o2 7 2
Crataegus pinnatiﬁda Bunge and other spp Shanzha; Hawthorn fruit 5 o2 6 2
Coix lacrima-jobi L. Yiyiren; Chinese pearl barley/Job's tears seeds 5 o2 4 1
Asparagus cochinchinensis (Lour.) Merr. Tianmendong; Chinese asparagus tuber 5 o2 3 o1
Leonurus sibiricus L. Yimucao; Chinese motherwort 5 o2 3 o1
Plantago depressa Willd. P. asiatica L. and other spp Cheqianzi; Plantain seed 5 o2 3 o1
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Table 2 (continued )
Botanical species source;
toxicity notes (where known, on shaded entries)
Herb: pinyin, common name(s) and plant part EU herbalists
citing herb
(n¼327)
Chinese
herbalists citing
herb (n¼348)
N Approx %
responders
N Approx %
responders
Aconitum spp. A. carmichaeli Debx.; A. kusnezofﬁi Richb. Toxic due to
alkaloids; prescription only in EU
Chuanwu; Common monkshood root Kusnezoff
monkshood root
4 o2 15 4
Ephedra sinica Stapf and other species. Legal restrictions in EU due to
ephedrine content.
Mahuang; Ephedra herb 4 1 9 3
Ligustrum lucidum W.T. Aiton Nuzhenzi; Glossy privet fruit 4 1 7 2
Epimedium brevicornu Maxim.; E. sagittatum (Siebold & Zucc.) Maxim. Yinyanghuo; Horny goat weed; barrenwort herb 4 o2 3 o1
Trichosanthes kirilowii Maxim (fruit/root/not speciﬁed) Gualou (fruit), Gualoupi (bark), Gualouzi (seed)
Tianhuafen (root): Mongolian snakegourd)
4 o1 3 o1
Morus alba L. and other spp. Sangshenzi (fruit); Sangye (leaf); sangbaipi (root bark);
White mulberry.
4 1 3 o1
Amomum villosum Lour (¼Cardamomum villosum (Lour.) Kuntze Sharen; villous amomum fruit 4 1 2 o1
Viscum species. Potential toxicity due to lectin/agglutinin content Hujisheng; Mistletoe herb/twig 3 o1 10 3
Millettia dielsiana Harms; Spatholobus suberectus Dunn. Jixueteng; Diel's millettia stem 3 o1 6 o2
Alisma plantago-aquatica subsp. Orientale (Sam.) Sam. (¼Alisma
orientale (Sam.) Juz.)
Zexie; Oriental water plantain rhizome 3 o1 1 o1
Taraxacum ofﬁcinale Webb Pugongying; Dandelion herb 3 o1 2 o1
Pseudostellaria heterophylla (Miq.) Pax Taizishen; False starwort root 2 o i 4 1
Platycodon grandiﬂorus (Jacq.) A.DC. Jiegeng; Balloon ﬂower 2 o1 5 1
Prunus armeniaca L. Potential toxicity (cyanide release from
amygdalin)
Xingren; Apricot kernel 2 o1 7 2
Hordeum vulgare L. Maiya; Malt; Germinated barley 2 o1 9 3
Eclipta prostrata (L.) L. (¼E. alba (L.) Hassk. Mohanlian, Hanliancao; Trailing/White eclipta herb 2 o1 3 o1
Dictamnus albus L. (¼Dictamnus dasycarpus Turcz.) Baixianpi; Dittany root bark 2 o1 2 o1
Notopterygium incisum C.T. Ting ex H.T. Chang. †Endangered species. Qianghuo; Notopterygium root and rhizome 1 o1 12 3
Achyranthes bidentata Blume Niuxi; Ox Knee 1 o1 12 3
Atractylodes lancea (Thunb.) DC. Cangzhu; Lance-leaved atractylodes rhizome 1 0 9 3
Clematis chinensis Osbeck, C. hexapetala Pall.; etc Weillingxian; Chinese Clematis/Traveller's Joy root 1 o1 5 1
Polygonatum odoratum and others Yuzhu; Scented Solomon's seal rhizome 1 o1 6 o2
Commiphora myrrha (Nees) Engl. and other spp. Moyao; Myrrh resin 1 o1 6 o2
Magnolia ofﬁcinalis Rehder & E.H. Wilson. Houpo, Magnolia bark; Xinyi, Magnolia ﬂower. 2 o1 3 o1
Cornus ofﬁcinalis Siebold & Zucc. Shanzhuyu 2 o1 0 0
Paris polyphylla Sm. Zaoxiu/Chonglou; Paris rhizome 1 o1 3 o1
Oldenlandia diffusa (Willd.) Roxb. and O. corymbosa L. (¼Hedyotis
diffusa Willd. and ) and H. corymbosa (L.) Lam.)
Baihuasheshecao; Snake-Needle Grass, Spreading
Hedyotis herb
1 o1 4 1
Aucklandia lappa Decne (¼Saussurea lappa (Decne.) C.B. Clarke) † Muxiang; Saussurea, Costus root 1 o1 2 o1
Glehnia littoralis F. Schmidt ex Miq. Beishashen; Coastal glehnia root., 1 o1 0 0
Boswellia serrata Roxb. ex Colebr.; B. sacra Flueck. and other species Ruxiang; Mastic, Frankincense resin 0 0 6 o2
Eriobotrya japonica (Thunb.) Lindl. (¼Mespilus spp). Cited as ‘Medlar’;
but may be Loquat
Pipaye (loquat leaf); Japanese Medlar fruit/leaf (not
speciﬁed)
0 0 6 o2
Cistanche deserticola Y.C. Ma; C. tubulosa (Schenk) Wight† Roucongrong; Desert broom-rape herb 0 0 4 1
Dendrobium nobile Lindl.; D. ﬁmbriatum Hook, D, chrysopterum Schuit.
& de Vogel†
Shihu; Dendrobium stem 0 0 4 1
Senna tora (L.) Roxb, S. obtusifolia (L.) H.S. Irwin & Barneby (¼Cassia
tora L., C. obtusifolia L) etc.
Juemingzi; Cassia seed 0 0 4 1
Asarum sieboldii Miq. and other spp. Toxic: banned in the EU due to
aristolochic acid
Xixin; Wild ginger 0 0 3 o1
Schizonepeta tenuifolia Briq. Jingjie; Japanese catnip/mint herb 0 0 3 o1
Daemonorops draco (Willd.) Blume and other spp. Xuejie; Dragon's blood resin 0 0 3 o1
Carica papaya L./Chaenomeles speciosa (Sweet) Nak. (Species not
clear).
Fanmugua; Pawpaw, Papaya/Mugua, Japanese quince
(plant part not stated)
0 0 3 o1
Miscellaneous other individual herbs cited once or twice, and only by
respondents in 1 region
Various 0‡ 0 34 10
Notes: nThese ﬁve herbs were speciﬁcally named, since they are known to be popular; the others were responses to an open question.
† Endangered species. These are more likely to adulteration or falsiﬁcation if taken from the wild and may be CITES protected.
‡ No examples of herbs used by EU respondents only were found (i.e. not also cited by Chinese practitioners).
Shaded entries denote potential or real toxicity issues; but non-shaded herbs are not necessarily guaranteed safe.
Plants are listed in order of frequency of use in the EU, having been cited individually by name, by herbalists, and not as part of a set formula or patent medicine (although
they are almost always used in combination). NB: all preparations and plant parts are listed under the species name, to identify frequency of use of toxic or endangered
species. In some cases, the part of the plant or the method of processing was not speciﬁed by respondents. We do not imply clinical equivalence of different preparations of
the same species.
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thus more likely to get their CMM from a practitioner. Lingzhi is
readily available as a food supplement in the EU (where it is also
known by its Japanese name, reishi) and consequently practitioners
can refer patients to buy it over the counter as well as prescribe it.
Almost certainly, the range of CMM available in China is
much wider: over 10,000 medicinal plant and animal species arementioned in the Chinese literature, and almost 1400 CMM
manufacturers listed (Liu et al., 2009). Over a thousand herbs are
stated to be ‘commonly used’ and regional variations in the use of
herbs create further local differences (Weckerle et al., 2009), but
availability on the markets is lower, and since TCM-hospitals use
around 800 herbs (for example, see http://www.tcmtreatment.
com/medications.htm), this is probably the maximum availability
Table 3
Comparison of animal species and mineral-derived CMM usage by TCM practitioners in China and the EU.
Animal species source Pinyin and common names (and pharmaceutical name if not a direct
translation)
EU
data
China
data
Ostrea gigas Thunb. Muli; Oyster shell 3 4
Pheretima aspergillum Chen and other spp. Dilong; Earthworm/Ground dragon 1 14
Scolopendra subspinipes mutilans L. Koch Wugong; Centipede 1 4
Cervus elaphus L. and others Lujiao Shuang; Degelatinised deer horn 1 1
Haliotis diversicolor Reeve, H. asinina L. and others. Shijueming; Abalone/Sea-ear shell 1 3
Various species of fossilised large mammals Longgu; Fossil fragments/Dragon's bones 1 3
Hyriopsis cumingii Lea, Cristaria plicata Leach and others Zhenzhumu; Pearl shell; Nacre (Concha Margaritifera Usta) 1 –
Cervus elaphus L. and others Lujaiojiao; Antler glue 1 –
Ophiocordyceps sinensis (Berk.) G.H. Sung, J.M. Sung, Hywel-Jones & Spatafora
(¼Cordyceps sinensis (Berk.) Sacc.) Dongchongxiacao; Caterpillar fungus; ‘Winter worm, summer grass’
1 –
Cryptotympana pustulata Fabricius Chantui; Cicada moulting, cicada slough 1 –
Bombyx mori L., infected with Beauveria bassiana Jiangcan; Stiffened/diseased silkworm (Bombyx Batryticatus) – 5
Gallus gallus L. Jineijin; Chicken gizzard-membrane – 4
Buthus martensii Karsch (BMK) (¼Mesobuthus martensii Karsch). Quanxie; Scorpion (Scorpio) – 3
Sepia esculenta Hoyle, or Sepiella maindroni de Rochebrune Wuzeigu, Haipiaoxiao; Cuttle-bone – 2
Bile (taken from ox, sheep or pig) with Arisaema. (Arisaema rhizome is toxic
unless processed).
Dannanxing; Bile with Arisaema
– 2
Whitmania pigra Whitman, Hirudo nipponica Whitman and others Shuizhi; Leech (Hirudo) – 1
Bufo gargarizans Cantor and others Toxicity due to cardioactive glycosides. Banmao; Toad skin, dried – 1
Equus asinus L. (or Equus africanus asinus L.) Ejiao; Donkey-hide gelatine (Colla Corii Asini) – 1
Mineral Pinyin and common names, chemical formula (and pharmaceutical
name if not a direct translation)
EU
data
China
data
Hydrated magnesium silicate Huashi; Talc; Mg3Si4O10(OH)2 – 1
Calcium sulphate dehydrate Shigao; CaSO4  2H2O (Gypsum Fibrosum) – 3
Notes: Shaded entries: toxicity suspected—may depend on processing and method of administration. This does not include possible contamination of animal tissues with
pathogens.
Number of citations is absolute, not a percentage of respondents.
Listed in order of use in the EU.
These materials are all cited individually by name by practitioners; they are not part of set formula or patent medicines although they are almost always used in combination.
ALL animal product citations are included.
E.M Williamson et al. / Journal of Ethnopharmacology 149 (2013) 453–462 459on the Chinese market. It is much lower in the EU and this was
reﬂected in our results.
Another major difference is the wide use of decoctions in China
compared to the EU. EU patients are accustomed to receiving their
medicines in a ‘ready-to-take’ form, rather than having to prepare
decoctions each day. Western herbalists also use alcoholic tinc-
tures (of all kinds of herbs) routinely, which is uncommon in China
(Luo et al., 2012).
4.2. Regulation
The more extensive use of TCM to treat neurological, cardio-
vascular and respiratory disease in China can be attributed to the
fact that in EU law, it is a criminal offence for a non-medical
practitioner to attempt to treat serious disease, including cancer.
Also, in China, it is culturally acceptable and even routine to treat
patients with a combination of TCM and Western medicine (Zhang
et al., 2011).
In China, the range of legal materials used is very much broader
and includes animal and mineral products unavailable in many EU
countries, for example, scorpion, toad skin, chicken gizzard mem-
brane and diseased silkworm, as well as arsenic and mercury salts.
The European Directive 2004/24/EC restricted the registration of
herbal products (which are allowed to make limited claims inform-
ing consumers of the conditions they are used to treat, on the basis
of traditional use) to those which had a proven history of use for 30
years, of which 15 years must be in the EU (Fan et al., 2012). So
there is the potential for some herbal CMM to be registered for
legitimate use in the EU but not the more toxic plants, minerals or
animal products. Other substances, if deemed safe, can be sold as
food supplements but no claims of any kind can be made.
In China also, more animal parts were used than in the EU. Many
of these are prohibited in the EU, although there is a thriving illicit
global market for items such as rhino horn and tiger bones, ashighlighted in the press. These items are less likely to be recorded in
the EU as comprehensively as other CMM because of their illegal
use, concerns from conservationists and emotive reports of animal
suffering. They are also extremely expensive and most practitioners
do not prescribe them (Graham-Rowe, 2011); instead they are
bought by the wealthy, over (or rather, under) the counter.
4.3. Safety
Chinese herbalists were far less likely to report seeing signiﬁ-
cant adverse events in practice. There may be many reasons for
this which are not obvious from our results and require further
investigation. It may be that TCM is indeed safer in China, due to
its long history and wide usage, although it may equally be the
case that pharmacovigilance of CMMs is less comprehensive in
China and events are simply not reported or collated (Zhang et al.,
2012). In the EU, various organisations including the German
Centre for Safety of Chinese Herbal Therapy (www.ctca.de) collect
reports on side effects of TCM-pharmacotherapy and hopefully
this practice may spread. Finally, as more serious diseases are
treated in China with TCM, outcomes are more likely to be less
beneﬁcial, which may be attributed solely to the disease and with
any role of the treatment being unrecognised.
Very few of the herbs being used in the EU in this sample of
practitioners give rise to safety concerns fromwhat is known from
the scientiﬁc and other literature. The main cause for concern is
likely to be interaction with prescribed medication, especially in
central nervous system and cardiovascular conditions, the most
likely therapeutic indications where drug interactions have been
reported to occur (Williamson, 2005); however, that is outside the
scope of this study. The range of substances used in China is more
likely to give rise to safety concerns as it is broader and the use of
certain toxic drugs is higher; however, even so, the majority of
herbs commonly used do not present a serious threat of harm, and
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of Aconitum toxicity in China, and in both Europe and China,
aristolochic acid (AA) poisoning. Aristolochia and Asarum species
both contain AA and are banned in the EU. A recent report
suggested that in Taiwan, the remarkably high incidence of upper
urinary tract urothelial carcinoma, at nearly 4 cases per 10, 000
people by 2007 (and four times higher than in the US) may be due
to the very wide usage of herbal medicines containing these
species (Chen et al., 2012a). No practitioners admitted to using
the drug but a small number of practitioners in China reported
using Asarum sieboldii (wild ginger). Aconite however is respon-
sible for repeated poisoning cases in Hong Kong, and can usually
be attributed to poor-quality herbs, and poor prescribing and
dispensing practice (Chen et al., 2012b). Aconitum is toxic in its
raw form (Wang et al., 2012) and also if not processed properly.
Three other herbs shown in Table 2 have potential safety
issues: Pinellia is toxic in its raw form because it contains high
levels of calcium oxalate (Liu et al., 2013) and also an agglutinin,
PTA, which has pro-inﬂammatory activity and enhances the
inﬂammation induced by the calcium oxalate raphides (Zhu
et al., 2012). Ephedra has legality issues due to its potential for
abuse as a CNS stimulant (due to the ephedrine content) in
excessive amounts (Normile, 2003), and peach and apricot kernels
(Prunus spp.) are toxic in large quantities as they contain amygdalin,
which releases cyanide gas on hydrolysis (Haque and Bradbury,
2002). These however are most toxic if consumed in the raw state;
there is less of a problem when used in decoctions, the standard
application form of Chinese pharmacotherapy. Prunus is not
subjected to a speciﬁc detoxiﬁcation process before use and can
be used peeled or unpeeled. Blanching with hot water before
peeling reduces the amygdalin content by about 50%. Further
details on processing methods can be obtained from the review by
Zhao et al. (2010).
Tripterygium wilfordii is used only in serious disease due to its
known serious side effects including infertility, dysmenorrhoea,
embryo damage, cardiac damage and even death (Law et al., 2011).
Many toxic CMM are not plant-based, and include minerals e.g.
cinnabar, realgar etc, as well as animals (Liu et al., 2013). The
regulatory position in the EU means that many of these minerals
are listed as poisons, and there are import restrictions on all
animal materials, in addition to regulations governing endangered
species. If Statutory Regulation for practitioners is introduced, as
has been proposed, herbalists may be able to access a wider range
of CMMs as ‘specials’, subject to the necessary approval (MHRA,
2006), but import restrictions are unlikely to be relaxed.
4.4. Patient characteristics and health conditions treated
The use of different CMM in the EU may reﬂect a different
patient population and health conditions for those using either
consulting TCM practitioners or self-medicating. For instance,
liuweidihuang is commonly used for older peoples' health, which
may explain its popularity in China with its rapidly increasing
older population, but this equally applies to Europe and ‘kidney
yin deﬁciency’ includes many female as well as degenerative
disorders (Huang et al., 2012). It has been reported that age,
gender and culture are indicators of complementary and alter-
native medicine usage (Williamson et al., 2013): therefore older
people, especially women, in China will know of this herb,
whereas European patients are less likely to.
Chinese practitioners cited treating neurological conditions,
mainly stroke and pain, which were rarely mentioned by European
herbalists, in accordance with EU law. This difference also relates
to the accepted treatments for stroke: in China, stroke patients are
treated with TCM immediately post-stroke with a combination of
physiotherapy, acupuncture and herbs, whereas patients in the EUwho elect to use TCM would not be seen by a practitioner until
they are released from primary care—usually after 4–6 months, if
at all (Chen et al., 1997). Pain is more commonly treated with
acupuncture in the EU, which may relate to the type of pain being
treated: in the EU, acute, muscular pain (which responds well to
acupuncture) is the most common indication, whereas in China,
pain due to serious underlying conditions such as angina pain,
renal colic, and cancer is treated with both CMM as well as
acupuncture (Ling et al., 2007).
EU practitioners were more likely to cite treating psychiatric
conditions and stress, obstetric, gynaecological and dermatological
conditions with TCM, which may be due to the differing
treatment-seeking patterns and healthcare culture in the two
areas. Mental health is not seen as a primarily medical issue in
China, where mental disorders are more likely to be dealt with
using self-management and family/peer support: one study found
that 88% of individuals with non-psychotic mental disorders had
never received any type of professional help for psychological
problems (Phillips et al., 2009). A similar situation may be
observed with obstetric and gynaecological issues: in China, girls
regard questions about menstruation and potential gynaecological
examination as threatening and embarrassing and most would
seek advice from family members (mostly their mothers and
friends) before considering seeking medical advice (Chan et al.,
2009). Cancer is not commonly treated by TCM alone in China, but
the practice of supporting chemotherapy with CMM is well-known
in both China and the EU and a new product, PHY906 based on
a traditional TCM formula, is now showing excellent promise
for enhancing efﬁcacy and attenuating side effects of many
chemotherapy agents (Liu et al., 2013).
4.5. Limitations of the study
Different sample sizes and sampling procedures were used for
EU and China, due to the variation in the organisation of the
profession (professional bodies and registers of practitioners,
geographical location, etc.), and although unavoidable, were
a potential source of bias. In the case of the EU, data collection
was dependent on the survey link being sent to members by the
administration of the relevant professional bodies. In China, only
TCM hospitals, rather than Western hospitals (who have TCM
departments), were targeted, which may have inﬂuenced the
results, and the Chinese sample also targeted large urban areas.
The ﬁndings should therefore be interpreted and extrapolated
with caution, given the relatively small sample size of practitioners
surveyed and differences in sampling techniques. Furthermore, a
number of Chinese practitioners said they ‘did not use’ these
herbs, but then speciﬁed they did in fact use them within
formulae, which are more common in China (Yuan and Lin,
2000). Such recipes include standard formulae from classical texts
and those prepared by practitioners to their own recipes.5. Conclusions
CMM were generally more commonly used for obstetric/
gynaecological and dermatological conditions in the EU, compared
to neurological and gastrointestinal disorders in China, reﬂecting
the previous ﬁndings for acupuncture practice (Robinson et al.,
2012). Of the speciﬁc herbs and formula cited in the questionnaire,
although there were differences in regional use, our results
conﬁrm their universal popularity and support the consensus
method of selecting them for the survey. In China, toxic herbs
were more widely used, as were animal-derived CMM such
as earthworm (rather more exotically known as ‘ground dragon’;
dilong), centipede (Scolopendra spp., wugong) and ‘fossil’ or
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broader, probably due to less strict regulation, wider availability
and lower cost, but also greater acceptance by patients. However,
the difference between the most widely used substances was less
marked than anticipated.
The use of CMM appears largely safe in both areas, apart from
potential safety issues with Pinellia, Prunus, Tripterygium, and
Aconitum in particular. These herbs have legal restrictions in the
EU and are usually subject to speciﬁc detoxiﬁcation processes
before use in China. The reported lower frequency of adverse
effects in China needs further exploration to investigate whether
TCM is actually safer in China, whether there is a cultural
perception that it is, or if adverse events are simply not widely
recorded. Surprisingly, some well-documented, highly toxic CMM,
such as croton seed (Croton tiglium L.; badou), black hellebore root
(Veratrum nigrum L.; lilu), and the animal medicine Cantharides or
blister beetle (Mylabris spp; banmao), were not cited at all by any
of the practitioners surveyed, suggesting that the use of these
materials may be much less widespread than expected, and less of
a public health problem than feared.
In summary, this survey, the ﬁrst of its kind, suggests that in
general, the species used in CMM currently most used by EU
practitioners are unlikely to cause serious adverse events.
In future, larger surveys are required to conﬁrm our ﬁndings, but
logistically these are very difﬁcult to carry out. Further recom-
mendations would be to ask practitioners to choose which herbs
they use from a speciﬁed list, to avoid omissions and use of
colloquial names, to explore the use of formulae and their
component herbs, and preparations such as injectables and
decoction granules.
As far as future beneﬁt is concerned, traditional medicine has
always supplied leads for the development of new drugs. China is
very rich in medicinal plant species, and many of these are also
used in other parts of the world. A recent study looking at shared
phylogenetic patterns across ﬂoras showed that related plants
from geographically disparate regions are used to treat medical
conditions in the same therapeutic areas, indicating independent
discovery of efﬁcacy. This interpretation was corroborated by the
presence of signiﬁcantly more known bioactive species than in
random samples (Saslis-Lagoudakis et al., 2012). Thus phyloge-
netic cross-cultural comparisons using herbal CMM could focus
screening efforts, and revitalize the use of traditional knowledge in
bioprospecting. This is in addition to the development of tradi-
tional formulae for modern use, as is the case with PHY906 as
cancer adjuvant therapy (Liu and Cheng, 2012), and both suggest
a bright future for TCM.Acknowledgements
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